OIRA Conclusion of EO 12866 Regulatory Review

RIN: 0910-ZA83         View EO 12866 Meetings	Received Date: 11/03/2020
Title: Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act ; Draft Guidance for Industry; Availability (2019-522)
Agency/Subagency: HHS / FDA	Stage: Notice
Concluded Action: Consistent without Change	Concluded Date: 11/12/2020
Legal Deadline: None	Economically Significant: No
Publication Date:	Unfunded Mandates: No
Major: No	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: No	Small Entities Affected: No
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No